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BACKGROUND: The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent
potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer.
METHODS: Real-time polymerase chain reaction analysis of 742 miRs was performed using plasma-derived circulating microvesicles
of 78 prostate cancer patients and 28 normal control individuals to identify differentially quantified miRs.
RESULTS: A total of 12 miRs were differentially quantified in prostate cancer patients compared with controls, including 9 in patients
without metastases. In all, 11 miRs were present in significantly greater amounts in prostate cancer patients with metastases
compared with those without metastases. The association of miR-141 and miR-375 with metastatic prostate cancer was confirmed
using serum-derived exosomes and microvesicles in a separate cohort of patients with recurrent or non-recurrent disease following
radical prostatectomy. An analysis of five selected miRs in urine samples found that miR-107 and miR-574-3p were quantified at
significantly higher concentrations in the urine of men with prostate cancer compared with controls.
CONCLUSION: These observations suggest that changes in miR concentration in prostate cancer patients may be identified by analysing
various body fluids. Moreover, circulating miRs may be used to diagnose and stage prostate cancer.
British Journal of Cancer (2012) 106, 768–774. doi:10.1038/bjc.2011.595 www.bjcancer.com
Published online 12 January 2012
& 2012 Cancer Research UK
Keywords: prostate cancer; microRNA expression; serum; plasma; urine

















































Prostate cancer is the most commonly diagnosed male malignancy
and the second leading cause of male cancer-related death (Jemal
et al, 2010). While community prostate-specific antigen (PSA)
testing can lead to the early detection and diagnosis of prostate
cancer this test has a low specificity, and the optimal threshold for
biopsy is unclear (Thompson et al, 2003). In addition, PSA
screening leads to the over diagnosis and over treatment of
indolent prostate cancers (Ciatto et al, 2000; Dall’Era et al, 2008).
In contrast, men receiving radical treatment for presumed locally
confined prostate cancer often develop disease relapse post
treatment, and in the majority of these patients the disease was
more extensive than it appeared pre-treatment.
MicroRNAs (miRs) are short non-coding RNA molecules with
an average length of 22 nucleotides (Catto et al, 2009). They are
transcribed as RNA hairpins and processed into mature miRs that
bind to complementary messenger RNA to alter gene expression
(Bartel, 2009). Currently around 1000 human miRs have been
identified and each of these may target around 1000 genes (Bartel,
2009) leading to a complex layer of control of signalling pathways
important to the development or progression of cancers (Croce,
2009). Several miRs have altered function or are differentially
present in prostate cancer (Catto et al, 2011). These appear to have
important mechanistic roles with respect to apoptosis avoidance,
proliferation, epithelial-to-mesenchymal transition and develop-
ment of androgen independence. MicroRNAs may be useful
biomarkers as their relatively small size protects them from RNase
attack and they are secreted within protective exosomes (Weber
et al, 2010). Several miRs have been shown to be upregulated in
sera of men with prostate cancer compared with normal controls
(Mitchell et al, 2008; Brase et al, 2011); however, to date most of
these studies contain small numbers of ill-defined patients.
Current investigations to detect and stage prostate cancer are
unable to detect micro-metastases (Rajarubendra et al, 2010).
Consequently, men with an undetectable low metastatic burden
undergo radical therapy for incorrectly presumed localised prostate
cancer. Therefore tests with greater staging accuracy are urgently
needed to accurately stratify patients. The aim of this study was to
perform a high-throughput analysis of a wide range of miRs in
serum and plasma samples of men with different stages of prostate
cancer and controls in order to identify those associated with the
presence and extent of prostate cancer. We also used urinary
samples to explore the identified miRs in another body fluid.
MATERIALS AND METHODS
Samples
ProMPT Plasma samples from prostate cancer cases (n¼ 78,
12 not evaluated for metastases, 51 M0, 15 M1) and normal control
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individuals (n¼ 28) were selected from men in the ProMPT
(Prostate Cancer Mechanisms of Progression and Treatment)
study. For the purposes of this study normal control individuals
were men with a PSA of o10 ngml1 who had undergone one or
more negative prostate biopsies. The study had ethics committee
approval (UK MREC number 01/4/61). After informed consent, BD
PPT K2E plasma samples were collected using vacutainer tubes
(Cat # 362799). Within 10min of blood draw, the blood samples
were centrifuged at room temperature using the Capricorn
CEP2000 for 20min at 2200 r.c.f. The samples were then aliquoted
and frozen at 80 1C within 24 h.
Urine samples enriched for prostatic cells were collected from
135 men following trans-rectal digital massage as described
elsewhere (Hessels et al, 2003). The first 5ml of voided urine
post-examination was collected, stored at 4 1C for up to 4 h and
then centrifuged at 3392 g for 10min. The supernatant was
removed and the cell pellet washed twice in PBS before freezing
at 80 1C until use.
University of Washington Serum samples were collected from
patients following radical prostatectomy who subsequently devel-
oped recurrent metastatic prostate cancer (n¼ 47) or who
subsequently had non-recurrent disease (n¼ 72). Serum from
non-recurrent prostate cancer patients was negative for PSA
in all cases. Patients with non-recurrent prostate cancer were
followed up with PSA measurements at 5 months or greater
post-surgery. Samples were collected in a serum separator tube
and serum was aliquoted in 1ml aliquots and kept frozen
at 80 1C. These samples were from the Genitourinary Cancer
Biospecimen Repository from the University of Washington
and had appropriate IRB approval (IRB approval number
39053). The samples were transferred to and stored at Caris Life
Sciences (Phoenix, AZ, USA) for analysis.
Sample preparation and RNA extraction
Plasma samples Frozen plasma samples were thawed and
enriched populations of cMVs were obtained by then filtering
the plasma through a 1.2-mm filter to remove cells and cellular
debris. One ml of the filtrate was concentrated to 300 ml
final retentate volume on a filter concentrator with a 150-kDa
molecular weight cutoff. Samples were treated with Rnase A
(Ambion, Austin, TX, USA) before RNA extraction in order to
ensure that RNA was derived from cMVs. Total RNA from 150 ml
of concentrated cMV was extracted using a modified version of
the Qiagen miRNeasy extraction protocol and eluted in a final
volume of 150 ml. All samples were spiked with 25 fmol ml1 of
Caenorhabditis elegans miR 39 for use as a normaliser in
downstream analyses.
Serum samples In order to ensure that the RNA was from
cMVs 500ml of serum was treated with 3 mgml1 Rnase A. After
Rnase A treatment, to ensure that isolated RNA was indeed from
cMVs, the RNA was isolated with the ExoMiR extraction kit (Bioo
Scientific, Austin, TX, USA), according to the manufacturer’s
instructions. Samples were spiked with 25 fmol ml1 of C. elegans
miR-39 for use as a normaliser in downstream analyses.
The ExoMir extraction method is designed to isolate RNA from
the microvesicle and exosome portions of the serum sample.
A clarifying spin was performed in order to remove cellular
fragments before the samples were pushed through the filters.
The serum samples were pushed through two different sized filters
(the first filter catches the larger microvesicles, while the second
filter catches the smaller exosomes sized between 20–200 nm) and
then the RNA was isolated by eluting the sample off the filters with
lysis solution.
Urine samples Total RNA was extracted from thawed cell
pellets using the mirVana kit (Ambion) according to the
manufacturer’s protocol and measured using a 2100 Bioanalyzer
(Agilent, Cheshire, UK).
qRT–PCR screening
In total 40 ng of RNA from plasma samples was reverse-
transcribed using the miRCURY LNA Universal RT miR PCR,
polyadenylation and cDNA synthesis kit. This amount of RNA was
chosen in order to ensure that there was enough input material for
the Exiqon qRT–PCR microarray panels to work. cDNA was then
screened using qRT–PCR on the miR ready-to-use PCR Human
Panel Iþ II (Exiqon Inc., Woburn, MA, USA) on an ABI 7900
Sequence Detection System.
qRT–PCR verification
Selected miRs were measured using Taqman human miR assays
(Life Technologies, Carlsbad, CA, USA). In brief, 3 ml of RNA was
reverse transcribed using the multi-scribe reverse transcriptase kit
for each assay studied. cDNA was pre-amplified with molecular
grade nuclease-free water as a diluent, and the cDNA was then
assessed using the Taqman qRT–PCR assay following manufac-
turer recommendations on an ABI 7900 Sequence detection
system. Serum and urine samples were assessed by the same
method with the only exception that the initial reverse transcrip-
tion reaction was carried out with a custom multiplex primer mix
specific to the assays being assessed. Absolute quantification was
measured by creating a standard curve for each assay.
Statistical analysis
The miR ready-to-use PCR Human Panels Iþ II (Exiqon Inc)
contain inter-plate as well as reverse transcription calibrators.
These were used to normalise the data after it was exported
to GeneSpring GX v11 (Agilent, Santa Clara, CA, USA) for
analysis. Normalised values for all prostate cancer vs controls,
non-metastatic prostate cancer vs controls and non-metastatic
vs metastatic analyses were subjected to a fold-change analysis.
Those miRs found to have a fold change greater than 2 were then
subjected to an unpaired t-test. The Benjamini and Hochberg false
detection test (Wang et al, 2009) was applied to the whole data set.
Taqman verification assays were analysed by first normalising the
CT of a selected assay to the C. elegans miR-39 Taqman CT for the
same sample. This value was multiplied by the copy number for a
selected assay to arrive at the corrected copy number. Assay median
copy numbers for each group compared were assessed using a Mann–
Whitney U test. This spike-in method of normalisation was chosen
because the frequently used sno normalisers are not expressed in
cMVs. For the urinary samples, we normalised miR expression to
the mean of two reference snoRNAs (RNU44 and RNU48).
For the multivariate PSA and miR analysis of the Taqman data,
we reviewed the original data set for missing data patterns. A
subset of n¼ 103 subjects (25 control individuals and 78 prostate
cancer patients) were identified with complete data for PSA and
miRs 107, 130b, 326, 301a, 185, 625 and 2110 (other miRs showed
extensive missing data patterns and were excluded). We con-
sidered each miR as a possible class differentiator for prostate
cancer, and only two miRs (miRs 107 and 326) were significantly
associated with prostate cancer at the P¼ 0.1 comparison-wise
level, suggesting that any association between marker and disease
outcome is likely to be weak. In contrast to the miR data, the use of
PSA level as a predictor of disease was more robust as it returned a
P-valueo1E-5. For completeness, we assessed the performance of
these miR markers with and without PSA using various predictive
modeling techniques (e.g., support vector machines, diagonal linear
discriminant analysis and logistic regression). Base models (PSA
alone) had AUCs generally in the order of 0.75. Models with miRs
and AUCs were 0.75–0.80. The results for multivariate models
were therefore consistent with univariate tests and demonstrated
that miRs did not show evidence either individually or collectively
of being able to improve the detection of prostate cancer.
MicroRNA expression in prostate cancer patients
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Support vector machines and their corresponding ROC curves
and AUC statistics were fit in R 2.12 (R development Core Team,
Vienna, Austria, 2011 ISBN 3-900051-07-0) using the CMA package
(Slawski et al, 2008).
RESULTS
Patients and samples
The demographics and clinical characteristics of the 106 ProMPT
plasma sample patients, 135 ProMPT urine sample patients and
119 University of Washington serum sample patients are outlined
in Table 1. An overview of the miR analysis of plasma, serum and
urine samples outlined in this manuscript is presented in Figure 1.
qRT–PCR array identification of miRs associated with
prostate cancer
First, we performed an analysis of plasma-derived cMVs in the 78
cancer cases and 28 controls within the ProMPT study, using an
Exiqon qRT–PCR microarray panel of 742 miRs. A total of 12
miRs were differentially quantified, 11 were significantly increased
in the plasma-derived cMVs of prostate cancer patients compared
with normal control individuals, while the concentration of
miR-181a-2* was significantly decreased (Po0.05 unpaired t-test)
(Table 2A). We then analysed plasma-derived cMVs from 55
non-metastatic prostate cancer patients and 28 normal control
individuals to identify miR changes associated with the presence
of non-metastatic disease. In all, 10 miRs were found to be
differentially quantified, 9 miRs showed a significant increase,
while miR-181a-2* showed significant decrease in the plasma
cMVs of prostate cancer patients without distant metastases
compared with normal control individuals (Po0.01 unpaired
t-test) (Table 2B). We then compared the miR profiles of 16
patients with metastatic and 55 patients with non-metastatic
prostate cancer. A total of 16 miRs were found to be differentially
quantified in prostate cancer patients with metastases compared
with those with non-metastatic disease. A total of 15 miRs showed
significantly greater concentration, whereas miR-572 was signifi-
cantly less (Po0.01 unpaired t-test) (Table 2C) in men with
metastatic vs non-metastatic prostate cancer.
Multivariate analysis of PSA and miRs
Multivariate analysis of the PSA values and the miR levels showed
that neither measure was superior in predicting prostate cancer. In
this cohort of non-metastatic prostate cancer patients compared
with biopsy confirmed normal individuals, PSA had an AUC of
Table 1 Characteristics of ProMPT (plasma and urine sample) and University of Washington (serum sample) patients
ProMPT University of
Washington
Plasma Urine Serum
Normal
controls
Prostate
cancer
Normal
controls
Localised
prostate cancer
Advanced
prostate cancer Non-recurrent Metastatic
Mean age (years) 63 70 69 69 73 59.9 69.6
Mean PSA ngml1 (s.d.) 5.69 (5.76) 86.4 (201.8) 4.1 (2.3) 9.6 (7.9) 63.6 (266.4) o 4.0 603 (794)
Median PSA ngml1 (IQR) 4.0 (2.1–7.8) 19.15 (7.9–44.1) 3.2 (1.7–6.9) 8.4 (1.3–22.3) 39.2 (19.2–530) N/A 324.6 (152.1–565)
Gleason scorea p6 — 33 — 52 12 46 4
7 — 19 — 14 18 25 5
X8 — 20 — 4 18 1 22
pT stage pTx — 4 — — — 1 16
PT1/2 — 35 — 70 — 64 —
PT3/4 — 39 — — 48 7 —
LN stage Nx — 73 — — — — —
N0 — 3 — — — — —
N1 — 2 — — — 1 —
M stage Mx — 12 — — — 72 0
M0 — 51 — — — — —
M1 — 15 — — — — 47
ADT Yes — — — 7 37 0 33
No — — — 63 11 72 14
Total (n) 28 78a 17 70 48 72 47
Abbreviations: ProMPT¼ Prostate Cancer Mechanisms of Progression and Treatment; PSA¼ prostate-specific antigen; IQR¼ interquartile range. aGleason Score data available
for 72 of 78 ProMPT plasma samples.
Plasma: diagnostic
Serum: prognostic
Urine:
Microarray 
qRT–PCR validation
qRT–PCR
qRT–PCR
79 Prostate cancers
28 Controls
47 Recurrent
72 Non-recurrent
17 Controls
70 Local cancer
48 Advanced cancer
Validated panel
Figure 1 Overview of miR analysis of plasma, serum and urine samples.
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0.79 with a sensitivity of 75% and a specificity of 46% at 4 ngml1.
In contrast, miR-107 had a sensitivity of 67% and a specificity
of 43% at 3000 copies and an AUC of 0.62. Combining PSA and
miR-107 and 141 did not enhance the performance of either assay
in detecting prostate cancer.
In the metastatic vs non-metastatic prostate cancer cohort, 77
samples characterised as either M0 or M1 were assayed by
individual Taqman qRT–PCR for five miR markers (miRs 375,
107, 200b, 141 and 452) found to have either significant or non-
significant expression differences in the initial Exiqon qRT–PCR
microarray panel. Of these markers miR 375 and 141 were
individually significantly associated with metastatic disease
(Po0.01) by unequal variance t-test. To estimate the combined
predictive value of these two miRs, with and without PSA, we
formed support vector machine classification models using a linear
kernel. Both methods performed well (estimated AUCs of 0.80 for
each), suggesting the potential predictive value of a miR-based test.
However, given the limited sample size of this data set it was not
possible to determine whether the combination of miR and PSA
measurement improved upon the model using miR alone.
qRT–PCR confirmation of miRs associated with prostate
cancer
Taqman qRT–PCR assays were performed in order to validate the
Exiqon qRT–PCR microarray panel miR quantification changes
identified in our ProMPT plasma samples. MicroRNA-107 and
miR-574-3p were increased in cMVs of men with non-metastatic
prostate cancer compared with normal control individuals
(Po0.05 Mann–Whitney U test). MicroRNA-141, miR-375 and
miR-200b were differentially quantified in men with metastatic
prostate cancer compared with individuals with non-metastatic
disease (Po0.05 Mann–Whitney U test). MicroRNA-375 and
miR-141 concentrations were found to be highly correlated with
an r2¼ 0.55 (Spearman correlation test Po0.001).
Confirmation of the metastatic miR signature
In order to confirm the metastatic miR signature identified in the
ProMPT plasma samples, we performed an analysis of an
independent serum cohort from the University of Washington.
This cohort consists of separate microvesicle and exosome
portions taken from sera from 47 patients with prostate cancer
metastases and 72 patients with non-recurrent prostate cancer. We
were interested in examining both the MV and exosome portion
separately, as the plasma concentration method used to gather the
cMVs collects both portions, and we wished to see if there was a
difference in miR quantification in these two blood fractions. This
analysis confirmed that miR-375 and miR-141 are significantly
increased in both the exosome (Figure 2) and microvesicle (data
not shown) portions of sera from patients with metastatic prostate
cancer compared with non-recurrent prostate cancer patients
(P¼ 0.0001 Mann–Whitney U test).
Urinary miR expression
Having observed numerous miR expression changes in the plasma
and serum of prostate cancer patients compared with normal
control individuals, we next investigated the possibility that some
Table 2A Analysis of all prostate cancer cases versus normal control
individuals
Normal control
individuals
Prostate
cancer
MiR
Normalised
CT value s.d.
Normalised
CT value s.d.
Fold
change
Corrected
P-value
107 5.10 5.20 1.50 4.20 11.26 0.034
130b 2.00 2.60 0.19 3.50 4.72 0.034
141 0.73 0.99 1.30 3.50 4.29 0.034
181a-2* 1.10 3.50 0.40 1.10 2.69 0.034
2110 1.90 3.20 0.69 4.20 6.13 0.035
301a 1.90 3.10 0.57 4.00 5.59 0.035
326 2.20 2.00 0.20 3.90 5.28 0.034
331-3p 2.00 3.30 0.43 4.10 5.39 0.043
432 0.70 1.00 1.10 3.20 3.5 0.035
484 1.90 3.10 0.37 2.30 2.87 0.47
574-3p 2.20 3.40 0.38 1.90 3.48 0.034
625* 0.68 1.00 1.20 3.40 3.76 0.035
Table 2B Analysis of localised prostate cancer cases versus normal
control individuals
Normal control
individuals
Localised
prostate cancers
MiR
Normalised
CT value s.d.
Normalised
CT value s.d.
Fold
change
Corrected
P-value
107 5.1 5.2 1.4 3.9 11.26 0.034
141 0.73 1 0.96 3.2 4.29 0.034
181a-2* 1.1 3.5 0.4 1.2 2.69 0.034
2110 1.9 3.2 0.66 4.2 6.13 0.035
301a 1.9 3.1 0.5 4.0 5.59 0.035
326 2.2 2 0.49 3.9 5.28 0.034
432 0.7 1 1.4 3.4 3.5 0.035
484 1.89 3.1 0.34 2.3 2.87 0.47
574-3p 2.17 3.4 0.44 1.9 3.48 0.034
625* 0.68 1 1.33 3.5 3.76 0.035
Table 2C Analysis of metastatic prostate cancer cases versus localised
prostate cancer cases
Localised
prostate cancer
Metastatic
prostate cancer
MiR
Normalised
CT value s.d.
Normalised
CT value s.d.
Fold
change
Corrected
P-value
582-3p 0.52 0.87 0.57 2.10 2.51 0.001
20a* 0.46 0.87 0.61 2.70 3.62 0.002
375 0.83 3.50 4.21 1.40 10.71 0.003
200b 0.21 1.70 1.60 3.60 3.90 0.003
379 0.43 0.87 0.38 2.00 2.10 0.005
572 0.63 3.70 2.70 1.40 7.39 0.005
513a-5p 0.44 0.87 0.46 2.36 2.23 0.005
577 0.15 2.38 1.64 3.96 5.90 0.005
23a* 0.46 0.87 0.49 2.53 2.30 0.005
1236 0.43 0.87 0.73 3.23 2.63 0.005
609 0.46 0.87 0.50 2.68 2.31 0.006
17* 0.29 2.40 2.40 4.12 4.80 0.006
619 0.28 1.41 0.80 2.52 3.37 0.008
624* 0.03 2.70 1.91 4.16 6.09 0.009
198 0.49 0.87 0.34 2.40 2.12 0.009
130b 0.47 3.20 2.18 3.60 6.12 0.007
Tables 2A, B and C: Exiqon qRT–PCR microarray panel-detected miR concentration
changes in plasma-derived circulating microvesicles associated with aspects of
prostate cancer. Eleven miRs were present in significantly greater amounts in prostate
cancer patients compared with normal control individuals (no prostate cancer) and
nine of these were increased in patients with localised prostate cancer (Po0.05
unpaired t-test). In both cases miR-181a-2* was present in significantly less
concentration. A total of 16 miRs were found to be present at different
concentrations in prostate cancer patients with metastases compared with those
with non-metastatic disease, 15 showed a greater concentration, while the
concentration of miR-572 was significantly decreased (Po0.01 unpaired t-test).
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of these miR changes might also be found in another fluid sample
that had been obtained from our cohort of men. We successfully
quantified the concentration of five selected miRs in 135 samples.
When RNA values normalised to the mean of RNU44/RNU48
(endogenous controls) were analyzed, we found that miR-107 and
miR-574-3p were present at significantly higher concentrations in
the urine of men with cancer when compared with controls
(ANOVA Po0.01, Table 3 and Figure 3). Both miRs could identify
the presence of prostate cancer from urine samples (concordance
indices 0.66–0.74) and appeared more accurate than PCA3
normalised to urinary PSA (concordance index 0.61).
DISCUSSION
Here, we have used high throughput profiling to identify 12 miRs
whose concentration is significantly different (11 miRs whose
concentration is significantly greater and 1 miR whose concentra-
tion is reduced) in the plasma and serum of patients with prostate
cancer, when compared with controls. We confirmed the finding of
two of these (miR-574-3p and miR-107) using individual Taqman
qRT–PCR assays in two new patient cohorts, using both serum
and urine. A total of 16 miRs were found to have significantly
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Figure 2 Taqman qRT–PCR analysis using an independent University of Washington serum cohort of exosome fractions verified the quantification
changes of miR-375 (A) and miR-141 (B) (P¼ 0.0001 Mann–Whitney U test).
Table 3 Quantification of selected microRNAs in urinary cells from
patients with prostate cancer and controls
DCt 95% CI ANOVA
Sample N Mean s.d. Lower Upper P-value
miR-107
Benign 17 10.90 5.18 8.24 13.56 0.001
Prostate cancer 113 7.93 2.86 7.40 8.47
ND 5
miR-574-3p
Benign 17 3.19 2.04 2.14 4.24 0.012
Prostate cancer 115 1.82 2.08 1.44 2.21
ND 3
miR-375
Benign 17 2.65 3.54 0.83 4.48 0.376
Prostate cancer 115 1.84 3.53 1.19 2.49
ND 3
miR-200b
Benign 17 2.35 2.12 1.26 3.44 0.533
Prostate cancer 116 1.91 2.83 1.39 2.43
ND 2
miR-141
Benign 17 4.94 2.12 3.85 6.03 0.752
Prostate cancer 115 4.73 2.62 4.24 5.21
ND 3
Abbreviation: ND¼ not detectable.
B 1.0
0.8
0.6
0.4
0.2
Se
ns
itiv
ity
0.0
0.0 0.2 0.4 0.6
miR-107 DCt (0.74)
PCA3 (0.61)
miR-574-3p (0.66)
0.8
1 - Specificity
1.0
15.00
miR-107A miR-574-3p
10.00
10.00P=0.001 P=0.012
5.00
5.00
–5.000.00
Prostate
cancer
BenignBenign Prostate
cancer
0.00
Figure 3 MicroRNAs-107 and 574-3p in urinary prostate cells are
associated with the presence of cancer. (A) The quantity (shown as DCt
values with respect to reference snoRNAs) is higher in prostate cancer
cases, when compared with controls. (B) This quantification can be used to
identify the presence of prostate cancer from urine samples (AUC ROC
shown in brackets).
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altered concentrations in metastatic prostate cancer patients
compared with non-metastatic cases, 2 of which (miR-375 and
miR-200b) were confirmed by Taqman qRT–PCR assays. It is
noted that the patients in our validation cohort had a median PSA
of 324.6 compared with a median PSA of 39.2 in our discovery
cohort, and this suggests that patients in the validation cohort had
a higher burden of disease. Despite this it is noteworthy that we
were able to observe changes in particular miR species in two
separate cohorts of patients with metastatic prostate cancer
compared with those with non-metastatic disease.
Several of these miRs are associated with prostate cancer for the
first time to the best of our knowledge, while other miR species,
such as miR-141 and miR-331-3p, have been associated with
prostate cancer in previous studies (Wang et al, 2009). We
included an individual Taqman qRT–PCR analysis of miR-141 in
our experiments in both the initial plasma cohort and the
subsequent serum validation cohort, as miR-141 changes in
prostate cancer have been reported in the literature, even though
the difference in miR-141 quantity did not reach statistical
significance in our initial Exiqon qRT–PCR microarray panel
screen. A case–control study of 25 metastatic prostate cancer
patients and 25 healthy age-matched male controls demonstrated
that the concentration of miR-141 is 46-fold greater in men with
metastatic prostate cancer, and measurement of serum levels of
miR-141 distinguished patients with metastatic prostate cancer
from healthy individuals (Mitchell et al, 2008). The results of our
study, taken together with others in the literature, suggest that the
incorporation of an assay measuring plasma miR-141 concentra-
tion within a diagnostic test for metastatic prostate cancer may be
clinically useful, particularly within the context of identifying
micro-metastatic disease in patients potentially undergoing radical
local therapy such as prostatectomy in the presence of a falsely-
negative radionuclide bone scan.
A recent combined differential expression and co-expression
network analysis of lymphoblastoid cell lines derived from 62
patients with aggressive prostate cancer and 63 patients with non-
aggressive prostate cancer identified a panel of 7 differentially
expressed miRs associated with aggressive disease. This approach
demonstrates the fact that differential expression of particular
miRNAs at germline level may dysregulate target hub genes in
prostate cancer cells thereby leading to abnormal cell division and
proliferation and the development of aggressive prostate cancer.
Interestingly, miR-331-3p was one of two miRs predicted to target
3 of the 20 hub genes associated with aggressive prostate cancer
(Wang et al, 2009). Our study of plasma samples has identified
miR-331-3p as being significantly associated with the presence of
prostate cancer, suggesting that this miR may be mechanistically
important in the development and/or progression of this
malignancy.
We identified nine miRs significantly upregulated and one miR
downregulated in patients with non-metastatic prostate cancer
compared with normal control individuals. Of these, we confirmed
the finding with miR-107 using an individual Taqman qRT–PCR
assay in both serum and urine. This observation suggests that an
individual assay of miR-107 concentration level may be a clinically
useful diagnostic test for non-metastatic prostate cancer. Further
studies are required to determine if this use of a miR-107 assay
using plasma samples may be sensitive and specific enough for use
as a single diagnostic test for non-metastatic prostate cancer,
followed by prostate biopsy or as part of a panel of measure-
ments including PSA and a subsequent biopsy. The utilisation of
assays such as plasma miR-107 measurement may potentially
improve the accuracy of conventional prostate cancer detection
and case finding when combined with PSA level measure-
ment, although this hypothesis requires formal testing in larger
prospective studies.
Our comparison of the miR profile of plasma samples
from patients with metastatic prostate cancer compared with
non-metastatic cases of this malignancy demonstrated 15 miRs
with significantly higher concentration and one miR with signi-
ficantly lower concentration in association with prostate cancer
metastases. The findings in two of these, miR-200b and miR-375,
were confirmed using Taqman qRT–PCR assays. MicroRNA-200b
and miR-375 have recently been shown to be increased in the
serum of patients with metastatic prostate cancer compared with
patients with localised disease (Brase et al, 2011), hence these miRs
might represent useful markers of micro-metastases in order to aid
appropriate selection of patients with organ-confined prostate
cancer for invasive therapy such as radical prostatectomy.
Although serum PSA measurement is extremely valuable in the
diagnosis of patients with established metastases, it is less accurate
in the identification of patients with occult micro-metastases,
potentially leading to inappropriate treatment choices such as
radical surgery. Our verification of the use of miR-141 and miR-
375 as markers of metastatic prostate cancer using independent
exosomal and microvesicle samples corroborates evidence from
other studies implicating miR-141 and miR-375 as useful candidate
markers of a metastatic prostate cancer signature (Brase et al,
2011). It is possible that assays measuring the concentration of
miR-141 and/or miR-375 may find clinical utility as biomarkers
incorporated into a suitable blood test for the differential diagnosis
of metastatic prostate cancer. This warrants further investigation
in a larger prospective study, particularly in the context of
detecting micro-metastases, which are too small to be detected
with conventional investigations such as radionuclide bone scans
or magnetic resonance imaging of bone marrow. A miR-based test
may possibly enable clinicians to distinguish more accurately
indolent or non-metastatic prostate cancer from aggressive disease
with metastatic potential. This distinction may facilitate the
selection of appropriate curative therapeutic options for patients
with potentially aggressive disease, enabling other patients with
more indolent disease to avoid complications and side effects
associated with over-treatment of prostate cancer.
In summary, we have demonstrated that changes in miR
concentration may be detected in plasma and serum samples
and may be useful as an aid in the diagnosis of prostate cancer. We
have also identified a miR signature of localised or metastatic
prostate cancer, which may be useful in the identification of occult
micro-metastases. Blood-based assays of particular miR concen-
trations may represent novel and clinically beneficial tests for
different aspects of prostate cancer management and warrant
further investigation in large prospective patient cohorts.
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